FDG and Beyond.
Although many PET tracers are in use, FDG still is the most widely used in clinical oncology practice. FDG therefore deserves an in-depth discussion, which is even more interesting because of the huge increase in the molecular biology of glucose metabolism. Obviously, other tracers are of increasing importance as well, and these will be discussed in short.
Radiation Oncology, University Hospitals Leuven/KU Leuven, Louvain, Belgium. dirk.deruysscher@maastro.nl.|Maastricht University Medical Center, GROW, Maastro clinic, Louvain, Belgium. dirk.deruysscher@maastro.nl.
Dirk
D
De Ruysscher
Radiation Oncology, University Hospitals Leuven/KU Leuven, Louvain, Belgium.
Karin
K
Haustermans
Section for Biomedical Physics, University Hospital for Radiation Oncology Tübingen, Tübingen, Germany.
Daniela
D
Thorwarth
D019788:Fluorodeoxyglucose F18 / Q000493:pharmacokinetics*; D005710:Gallium Radioisotopes / Q000493:pharmacokinetics; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000379:methods; D009369:Neoplasms / Q000000981:diagnostic imaging* / Q000378:metabolism* / Q000532:radiotherapy; D049268:Positron-Emission Tomography / Q000379:methods*; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D014057:Tomography, X-Ray Computed / Q000379:methods
D005710:Gallium Radioisotopes; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18
FDG; Hypoxia; Molecular imaging; PET; Target volume; Tracer